Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06586281 · ClinicalTrials.gov registry record · NA
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
A NA study of Psoriatic Arthritis, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06586281: Recruiting NA study of Psoriatic Arthritis, sponsored by University of California, San Diego.
NCT06586281 is a NA study of Psoriatic Arthritis that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 20 participants, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06586281, a NA study of Psoriatic Arthritis, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients. Shared disease mechanisms may explain the increased severity in PsA. This study involves two visits from PsA patients with NAFLD and active disease signs (e.g., swollen joint, enthesitis, or psoriatic plaque). It aims to assess the impact of biological therapies on liver disorders, joints, and skin in PsA patients.
Primary Outcome
Defined by MRI-PDFF responders (relative change in liver fat ≥30%) vs non-responders (relative change in liver fat \<30%) at Week 24.
Conditions Studied
Interventions
- DRUG Guselkumab
Study Locations (1)
California
- University of California, San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2026-12-01 |
| Phase | NA |
What NCT06586281 shows while recruiting
NCT06586281 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Guselkumab is the first listed.
NCT06586281 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06586281 about?
NCT06586281 is a clinical study titled "Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy". While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients. Shared disease mechanisms may explain the increased severity in PsA. This study involves two visits from PsA patients with NAFL...
What is the current status of trial NCT06586281?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-06-01. Estimated completion is 2026-12-01.
What conditions does trial NCT06586281 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT06586281?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT06586281?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06586281 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06586281's enrollment target sits among peer trials
20 46th of 48 higher than 1 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
RECRUITING · NA
-
Psoriatic Arthritis D2P Screening
RECRUITING · NA
-
Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System
ACTIVE NOT RECRUITING · NA
-
Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity
ACTIVE NOT RECRUITING · NA
-
Improving Virtual Care of Arthritis: Integrating a Smartphone App Into the EHR for Improved Timeliness of Visits
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI